Company changes name to Bako Diagnostics and redesigns logo to reflect increased clinical laboratory services for podiatrists

ATLANTA. Dec. 15 /PRNewswire/ – Bako, a podiatry-focused clinical laboratory and products company, announced today the launch of its new, new company name and newly designed company logo. As a partner and advocate to the podiatric community, the website is designed to be a leading source of education, innovation and insight for podiatrists. The company’s new name and new logo reflects the evolution of the company from Bako Integrated Physician Services to Bako Diagnostics.

“We are excited to launch this new site that provides user-friendly access to all of Bako services, products and learning materials.” stated Larry McCarthy, Bako’s CEO.  “We will continue to modify this site as the needs of podiatrists evolve and new tests and technologies are introduced by our company.”

The new site has been optimized to provide a great user experience across all digital devices, including desktop and mobile. It includes a newly updated learning center, an educational resource for podiatrists and their staff, and a simple means for podiatrists to collaborate with Bako’s team of pathologists.

“Our new company name and logo, demonstrates the expansion of our laboratory services into the molecular diagnostics arena.” said Dan Spragle, President and COO. “We will continue to grow services while still providing podiatrists with our innovative and industry-leading pathology tests on which they have come to rely.”

Bako, headquartered in Alpharetta, GA with over 230 employees, serves as a specialty testing lab for clinicians of the lower extremity, providing their patients with easy access to affordable diagnostic testing and treatments.

Bako is proud to invest in the future of podiatry by funding a series of two-week fellowships in podiatric dermatology at their laboratory facility. Interested candidates can sign-up on the new website


Bako Diagnostics is a provider of diagnostic and therapeutic services with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 200 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies.  Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship.